Want to see TSE:TELI full AI Analyst Report?
Top Page
Telescope Innovations Corp
(TELI)
Select Model
Select Model
Rating:41Neutral
Price Target:
C$0.40
▼(-17.08% Downside)
Action:N/A
Date:09/24/26
The score is driven primarily by weak financial performance: very low margins, sizable losses, and worsening cash burn increase execution and financing risk despite strong reported revenue growth. Technicals add downside pressure with the price below key moving averages and bearish momentum indicators. Valuation remains hard to justify with negative earnings (negative P/E) and no dividend yield data.
Positive Factors
Rapid TTM Revenue Growth
The sharp TTM revenue increase indicates that the company is expanding its reported top line and gaining commercial activity. If retained, this growth can create operating leverage and provide a broader base from which management may improve profitability over the next several quarters.
Negative Factors
Very Weak Profitability
Extremely low gross margin and deeply negative operating and net margins show that current revenue is not translating into sustainable earnings. This weakens the quality of growth, limits internally generated funding, and suggests that substantial cost improvements are needed before scale can create durable profit.
Read all positive and negative factors
Positive Factors
Negative Factors
Rapid TTM Revenue Growth
The sharp TTM revenue increase indicates that the company is expanding its reported top line and gaining commercial activity. If retained, this growth can create operating leverage and provide a broader base from which management may improve profitability over the next several quarters.
Read all positive factors
Telescope Innovations Corp (TELI) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$24.65M
Dividend YieldN/A
Average Volume (3M)68.26K
Price to Earnings (P/E)5.7
Beta (1Y)0.40
Revenue Growth94.58%
EPS GrowthN/A
CountryCA
Employees22
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.06
Shares Outstanding80,805,300
10 Day Avg. Volume95,070
30 Day Avg. Volume68,256
Financial Highlights & Ratios
PEG Ratio-0.32
Price to Book (P/B)11.52
Price to Sales (P/S)4.83
P/FCF Ratio-34.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Telescope Innovations Corp Business Overview & Revenue Model
Company Description
Telescope Innovations Corp., a chemical technology company, develops manufacturing processes and tools for the pharmaceutical and chemical industry in the United States and Canada. It offers DIRECTINJECT-LCTM, a hardware and software ecosystem tha...
Telescope Innovations Corp Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
44
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Nov 2025 | Nov 2024 | Nov 2023 | Nov 2022 | Aug 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.30M | 4.78M | 4.27M | 2.82M | 595.40K | 0.00 |
| Gross Profit | 162.28K | 194.97K | 4.27M | 2.82M | 595.40K | 0.00 |
| EBITDA | -3.98M | -587.02K | -456.60K | -421.78K | -5.49M | -3.14M |
| Net Income | -4.09M | -1.56M | -1.32M | -718.09K | -5.73M | -4.03M |
Balance Sheet | ||||||
| Total Assets | 6.84M | 7.28M | 5.69M | 3.29M | 3.02M | 4.07M |
| Cash, Cash Equivalents and Short-Term Investments | 1.33M | 2.70M | 337.01K | 356.81K | 719.49K | 3.29M |
| Total Debt | 2.71M | 2.25M | 2.03M | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 3.45M | 5.27M | 4.17M | 713.18K | 1.35M | 247.07K |
| Stockholders Equity | 3.39M | 2.00M | 1.52M | 2.58M | 1.67M | 3.83M |
Cash Flow | ||||||
| Free Cash Flow | -6.26M | -672.66K | -19.80K | -1.79M | -2.57M | -1.54M |
| Operating Cash Flow | -5.69M | 252.06K | 19.80K | -1.76M | -1.37M | -941.00K |
| Investing Cash Flow | -572.38K | -924.72K | -39.60K | -35.77K | -1.20M | -599.57K |
| Financing Cash Flow | 6.48M | 3.04M | 0.00 | 1.43M | 0.00 | 4.79M |
Telescope Innovations Corp Technical Analysis
Negative
0.48
Price Trends
0.44
Negative
0.53
Negative
0.50
Negative
Market Momentum
-0.04
Positive
27.02
Positive
19.53
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:TELI, the sentiment is Negative. The current price of 0.48 is above the 20-day moving average (MA) of 0.37, above the 50-day MA of 0.44, and below the 200-day MA of 0.50, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 27.02 is Positive, neither overbought nor oversold. The STOCH value of 19.53 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:TELI.
Telescope Innovations Corp Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | C$122.35M | 28.16 | 15.04% | 6.94% | 4.11% | 88.39% | |
54 Neutral | C$41.09M | -8.50 | -18.83% | ― | -27.13% | -1752.63% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | C$37.19M | -11.36 | 12.68% | ― | 45.72% | 35.82% | |
42 Neutral | C$11.63M | -2.43 | 92.37% | ― | ― | 16.04% | |
41 Neutral | C$24.65M | 5.71 | 114.66% | ― | 94.58% | ― | |
41 Neutral | C$6.15M | -2.05 | 273.53% | ― | ― | ― |
* Healthcare Sector Average
TSE:TELI
Telescope Innovations Corp
0.31
-0.09
-21.79%
TSE:COV
Covalon Technologies
4.43
2.33
110.95%
TSE:HEM
Hemostemix
0.06
-0.04
-42.11%
TSE:KNE
Kane Biotech
0.03
0.00
0.00%
TSE:MBX
Microbix Biosystms
0.30
0.04
15.38%
TSE:MIR
Medmira
0.05
-0.02
-29.33%
Telescope Innovations Corp Corporate Events
Business Operations and Strategy
Telescope Innovations CTO Joins NSF’s US$380 Million Programmable Cloud Labs Kickoff
Positive
Sep 23, 2026
Telescope Innovations Corp. disclosed that its chief technology officer, Prof. Jason Hein, has been invited to participate in the National Science Foundation’s Programmable Cloud Laboratories Test Bed kickoff meeting in Washington, D.C., a h...
Business Operations and StrategyExecutive/Board Changes
Telescope Innovations Adds Veteran Chemist and Tech Founder Dr. Neil Lewis to Board
Positive
Aug 19, 2026
Telescope Innovations Corp., a developer of physical AI systems and autonomous Self-Driving Laboratories for pharmaceutical and high-value chemical companies, has appointed Dr. E. Neil Lewis to its board of directors. The Vancouver-based firm̵...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.